Aragon Pharmaceuticals is a San Diego based biopharmaceutical company focused on developing a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers.

Press ReleasesPress_Release_091027.html
ARN-509 Clinical TrialPress_Release_091027.html
http://clinicaltrials.gov/ct2/show/study/NCT01171898?term=NCT01171898&rank=1

ARN-509-001: Phase 1/2 Trial of ARN-509 in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer

View ARN-509-001 Clinical Trial Information at ClinicalTrials.govhttp://clinicaltrials.gov/ct2/show/NCT01171898?term=NCT01171898&rank=1http://clinicaltrials.gov/ct2/show/study/NCT01171898?term=NCT01171898&rank=1shapeimage_5_link_0
Press_Release_100802.html
August 2, 2010 Aragon Pharmaceuticals Appoints Richard A. Heyman CEOPress_Release_100802.html
Press_Release_100809.html
August 9, 2010 Aragon Pharmaceuticals Doses First Patient in Phase 1/2 Clinical Trial of ARN-509 for Castration-Resistant Prostate CancerPress_Release_100809.html